Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
protein degradation
Biotech
C4T halts BRAF degrader work to save cash for cemsidomide
C4 Therapeutics is ending work on its clinical-stage BRAF degrader program to focus on its IKZF1/3 degraded cemsidomide.
James Waldron
May 7, 2025 7:00am
Sanofi pays Nurix $15M upfront for autoimmune degrader
Apr 2, 2025 8:10am
Eli Lilly feels Magnet's pull with hefty molecular glue deal
Feb 28, 2025 6:30am
AbbVie crafts $1.6B deal with molecular glue biotech Neomorph
Jan 23, 2025 9:58am
Kymera pivots to immunology, seeks partners for cancer assets
Nov 1, 2024 11:46am
Biogen buys in to molecular glues with deal worth up to $1.45B
Oct 30, 2024 10:50am
